Investment Thesis
Despite reporting positive net income and 8% revenue growth, Amneal faces critical financial distress with negative stockholders equity (-$45.4M), negative operating cash flow (-$26.7M), and unsustainable debt burden ($2.6B). The stark divergence between positive net income ($62.3M) and negative operating cash flow signals severe earnings quality issues and working capital deterioration.
Strengths
- Revenue growth of 8% YoY demonstrates maintained market demand
- Solid gross margin of 44.3% and operating margin of 19.6% indicate reasonable unit economics
- Short-term liquidity adequate with current ratio of 2.47x and quick ratio of 1.59x
Risks
- Negative stockholders equity of -$45.4M indicates technical insolvency from balance sheet perspective
- Negative operating cash flow of -$26.7M despite positive net income reveals significant earnings quality concerns
- Negative free cash flow of -$34.9M with $2.6B debt burden creates unsustainable capital structure
- Net income growth stalled at 0% YoY while revenue grew 8%, indicating margin compression and operational stress
- Very low ROA of 1.8% on $3.5B asset base suggests poor asset utilization
- Cash runway concerns with only $197.7M cash against $2.6B debt and negative cash generation
Key Metrics to Watch
- Operating cash flow trend - must turn positive to validate earnings quality
- Stockholders equity trajectory - path to positive equity is critical
- Debt refinancing capability and covenant compliance given negative cash generation
- Working capital management - identify sources of cash flow deterioration
- Revenue retention and margin sustainability in competitive generic pharma sector
Financial Metrics
Revenue
722.5M
Net Income
62.3M
EPS (Diluted)
$0.19
Free Cash Flow
-34.9M
Total Assets
3.5B
Cash
197.7M
Profitability Ratios
Gross Margin
44.3%
Operating Margin
19.6%
Net Margin
8.6%
ROE
N/A
ROA
1.8%
FCF Margin
-4.8%
Balance Sheet & Liquidity
Current Ratio
2.47x
Quick Ratio
1.59x
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
2.6B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T07:47:17.483748 |
Data as of: 2026-03-31 |
Powered by Claude AI